| Ryan Paul Floyd, MD | |
|
200 Village Dr, Suite C, Greensburg, PA 15601-3783 | |
| (724) 834-6900 | |
| (724) 834-2896 |
| Full Name | Ryan Paul Floyd |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 11 Years |
| Location | 200 Village Dr, Greensburg, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699112797 | NPI | - | NPPES |
| 1031184820001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD455936 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Excela Health Home Care & Hospice | Greensburg, PA | Home health agency |
| Excela Health Latrobe Hospital | Latrobe, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Excela Health Physician Practices, Inc | 6204737117 | 438 |
News Archive
CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.
Consumers are increasingly buying food from mass merchandisers, warehouse clubs, and convenience stores, but are selecting foods with poor nutritional profiles, according to new study in the American Journal of Preventive Medicine
Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines, today announced that it has raised $15 million in a Series C financing round. OrbiMed Advisors LLC led the round, with participation from existing investors Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments. The Series C financing brings the total capital raised by Selecta over the past 15 months to more than $30 million.
Females often live longer than men - this is true for humans and for many other animal species. The phenomenon exists even when you adjust for male risky behavior which leads to more early male deaths than female (car accidents, wars, homocides, etc).
Fewer prostate cancers were detected by prostate-specific antigen (PSA) screening in the U.S. than in a European randomized trial because of lower screening sensitivity, according to a new brief communication published online February 8 in the Journal of the National Cancer Institute.
› Verified 1 days ago
| Entity Name | Latrobe Area Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336166974 PECOS PAC ID: 4183525595 Enrollment ID: O20040119000382 |
News Archive
CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.
Consumers are increasingly buying food from mass merchandisers, warehouse clubs, and convenience stores, but are selecting foods with poor nutritional profiles, according to new study in the American Journal of Preventive Medicine
Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines, today announced that it has raised $15 million in a Series C financing round. OrbiMed Advisors LLC led the round, with participation from existing investors Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments. The Series C financing brings the total capital raised by Selecta over the past 15 months to more than $30 million.
Females often live longer than men - this is true for humans and for many other animal species. The phenomenon exists even when you adjust for male risky behavior which leads to more early male deaths than female (car accidents, wars, homocides, etc).
Fewer prostate cancers were detected by prostate-specific antigen (PSA) screening in the U.S. than in a European randomized trial because of lower screening sensitivity, according to a new brief communication published online February 8 in the Journal of the National Cancer Institute.
› Verified 1 days ago
| Entity Name | Excela Health Physician Practices, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821225202 PECOS PAC ID: 6204737117 Enrollment ID: O20040322001393 |
News Archive
CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.
Consumers are increasingly buying food from mass merchandisers, warehouse clubs, and convenience stores, but are selecting foods with poor nutritional profiles, according to new study in the American Journal of Preventive Medicine
Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines, today announced that it has raised $15 million in a Series C financing round. OrbiMed Advisors LLC led the round, with participation from existing investors Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments. The Series C financing brings the total capital raised by Selecta over the past 15 months to more than $30 million.
Females often live longer than men - this is true for humans and for many other animal species. The phenomenon exists even when you adjust for male risky behavior which leads to more early male deaths than female (car accidents, wars, homocides, etc).
Fewer prostate cancers were detected by prostate-specific antigen (PSA) screening in the U.S. than in a European randomized trial because of lower screening sensitivity, according to a new brief communication published online February 8 in the Journal of the National Cancer Institute.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ryan Paul Floyd, MD 520 Jefferson Ave, Suite 400, Jeannette, PA 15644-2538 Ph: (724) 527-8060 | Ryan Paul Floyd, MD 200 Village Dr, Suite C, Greensburg, PA 15601-3783 Ph: (724) 834-6900 |
News Archive
CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.
Consumers are increasingly buying food from mass merchandisers, warehouse clubs, and convenience stores, but are selecting foods with poor nutritional profiles, according to new study in the American Journal of Preventive Medicine
Selecta Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vaccines, today announced that it has raised $15 million in a Series C financing round. OrbiMed Advisors LLC led the round, with participation from existing investors Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments. The Series C financing brings the total capital raised by Selecta over the past 15 months to more than $30 million.
Females often live longer than men - this is true for humans and for many other animal species. The phenomenon exists even when you adjust for male risky behavior which leads to more early male deaths than female (car accidents, wars, homocides, etc).
Fewer prostate cancers were detected by prostate-specific antigen (PSA) screening in the U.S. than in a European randomized trial because of lower screening sensitivity, according to a new brief communication published online February 8 in the Journal of the National Cancer Institute.
› Verified 1 days ago
William J Monsour, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: Route 136 West, Greensburg, PA 15601 Phone: 724-836-4473 Fax: 724-836-3835 | |
Jacob A Dicesare, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 438 Pellis Rd, Greensburg, PA 15601 Phone: 724-261-4080 Fax: 724-261-4081 | |
Dr. Thomas Richard Degregory, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 372 Lakewood Rd, Greensburg, PA 15601 Phone: 724-219-4489 Fax: 724-832-1385 | |
Nabil Jabbour, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 337 Harvey Ave # A, Greensburg, PA 15601 Phone: 724-832-9378 Fax: 724-832-9384 | |
Karen A. Lang, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 Cameo Ln, Greensburg, PA 15601 Phone: 724-834-1326 Fax: 724-834-6685 | |
Dr. Matthew W Levin, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 259 Old State Route 30, Suite C, Greensburg, PA 15601 Phone: 724-216-9300 Fax: 724-216-9302 | |
Dr. Robert M Fetchero, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6321 Route 30 Fl 2, Greensburg, PA 15601 Phone: 724-671-1750 Fax: 724-523-7726 |